Full name

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B (anti-IL33) Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

NCT Number
NCT06979518
Geography
Non-US
Locations

TBD

Primary Endpoints
  • Number of Participants with Adverse Events (AE). Up to Week 44 (End of follow up visit)
  • Number of Participants with Serious Adverse Events (SAE). Up to Week 44 (End of follow up visit)
  • Number of Participants with Clinically Significant Changes in Clinical Laboratory Values. Up to Week 36
  • Number of Participants with Clinically Significant Changes in Vital Signs. Up to Week 36
  • Number of Participants with Clinically Significant Changes in 12-lead (Electrocardiogram (ECG). Up to Week 36
  • Area Under the Serum Concentration-time Curve Extrapolated to Infinity (AUC[0-inf]) of GSK3862995B. Up to Week 36
  • Maximum Observed Concentration (Cmax) of GSK3862995B. Up to Week 36
Order
6
Disease
COPD
Menu title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B (anti-IL33) Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Version
ACAAI 2025
Phase
1
Status
Not yet recruiting